Medtronic plc

  • TickerMDT
  • ISINIE00BTN1Y115
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

MEDTRONIC with less fundamental stars is reduced to Neutral

MEDTRONIC (US), a company active in the Medical Equipment industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 3 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date January 19, 2021, the closing price was USD 118.31 and its expected value was estimated at USD 114.52.

Medtronic Plc: 1 director sold

A director at Medtronic Plc sold 15,000 shares at 114.900USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

MarketLine Department

DePuy Synthes Companies - Strategy, SWOT and Corporate Finance Report

Summary DePuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights DePuy Synthes Companies (DePuy Synthes, or 'the company'), operates as a part of the medical device and diagnostics (MD&D) segment of Johnson & Johnson (J&J). DePuy offers a range of orthopaedic and neuro products and services various scenarios such as joint reconstruction, trauma, c...

MarketLine Department

Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Hill-Rom Holdings, Inc. (Hill-Rom) is a medical technology company that offers products, services and patient care solutions in the areas of patient monitoring and diagnostics, wound care and prevention, surgical safety and efficiency, respiratory health, and advancing mobility. The ...

MarketLine Department

Hologic, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Hologic, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Hologic, Inc. (Hologic) is a diversified medical technology company focused on improving women's health and well-being. The company is involved in manufacture and distribution of premium diagnostics products, medical imaging systems and surgical products for women. Hologic offers a range of di...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of Consumer Cyclical names continue to reflect leadership. (ex. SBUX, RRGB, MCD, PZZA, and ROST.) • The Financial Sector has a number of attractive names developing major bases and staging RS reversals. (ex. SIVB, STT, AXP, SPGI, CME, GS, and JEF) • The Technology Sector has a number of technically attractive constituents. (ex. AMD, OLED, MPWR, CRUS, BR, FIS, VRSN, SAIC, LDOS, AAOI, BELFB, FARO, STX, and AAPL) .

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

U.S. dollar breaking down; Gold breaking out The S&P 500 is consolidating under 2,954 - logical resistance - as market participants are in wait-and-see mode for incremental trade news ahead of the Trump/Xi G20 meeting later this week. While a breakout is certainly possible, we believe additional consolidation is the more likely scenario. Below we highlight a mix of positive and negative developments which lead us to this conclusion along with updates on other big picture trends. • U.S. dollar (DXY) breaking down, Treasury yields remain suppressed. Dovish Fed comments opened the door for ra...

Jérôme VINERIER

Analyse court terme - MEDTRONIC INC : La tendance est incertaine.

La tendance est incertaine. Les cours baissent, et il y a une possibilité d'accélération baissière. Une nouvelle tendance baissière tente de démarrer.

Medtronic Plc: 1 director sold

A director at Medtronic Plc sold 15,000 shares at 114.900USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

MarketLine Department

DePuy Synthes Companies - Strategy, SWOT and Corporate Finance Report

Summary DePuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights DePuy Synthes Companies (DePuy Synthes, or 'the company'), operates as a part of the medical device and diagnostics (MD&D) segment of Johnson & Johnson (J&J). DePuy offers a range of orthopaedic and neuro products and services various scenarios such as joint reconstruction, trauma, c...

MarketLine Department

Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Hill-Rom Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Hill-Rom Holdings, Inc. (Hill-Rom) is a medical technology company that offers products, services and patient care solutions in the areas of patient monitoring and diagnostics, wound care and prevention, surgical safety and efficiency, respiratory health, and advancing mobility. The ...

MarketLine Department

Hologic, Inc. - Strategy, SWOT and Corporate Finance Report

Summary Hologic, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Hologic, Inc. (Hologic) is a diversified medical technology company focused on improving women's health and well-being. The company is involved in manufacture and distribution of premium diagnostics products, medical imaging systems and surgical products for women. Hologic offers a range of di...

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or 'the company') is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic p...

MarketLine Department

Abbott Laboratories - Strategy, SWOT and Corporate Finance Report

Summary Abbott Laboratories - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Abbott Laboratories (Abbott or 'the company') is a pharmaceutical company that develops manufactures and markets a broad line of health care products. The company offers diagnostic systems, neuromodulation devices, medical devices, pediatric and adult nutritional products and generic pha...

Medtronic, Inc.: Excellent liquidity and business profile mitigate impacts from the coronavirus pandemic

Our credit view of Medtronic, reflecting its strong product diversification, offset by global pricing pressure and soft hospital admission trends.

Medtronic, Inc.: Update of key credit considerations

Our credit view of Medtronic reflects its leading position in the medical device industry and relatively low financial leverage.

Medtronic, Inc.: Update of key credit considerations

Our credit view of Medtronic reflects its leading position in the medical device industry and relatively low financial leverage.

Medtronic, Inc.: Update of key credit considerations

Our credit view of Medtronic reflects its leading position in the medical device industry and relatively low financial leverage.

Medtronic, Inc.: Medtronic's bond tender is credit positive, no immediate rating impact

Medtronic's proposed bond tender is credit positive as it will reduce interest costs and extend debt maturities

MEDTRONIC with less fundamental stars is reduced to Neutral

MEDTRONIC (US), a company active in the Medical Equipment industry, loses a star(s) at the fundamental level and sees its general evaluation downgraded. The independent financial analyst theScreener just removed a fundamental star(s) for a 3 over 4-star rating. As such, market behaviour remains unchanged and is evaluated as moderately risky. theScreener believes that the loss of a star(s) merits downgrade to the general evaluation of the title, which passes to Neutral. As of the analysis date January 19, 2021, the closing price was USD 118.31 and its expected value was estimated at USD 114.52.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch